Enrolling Studies

GS-0119

You may qualify for this study if the following applies to you:

  • HIV positive
  • CD4 ≥ 50
  • VL ≤ 50 copies/mL
  • History of at least one antiretroviral therapy prior to current regimen
  • Currently taking Raltegravir, Elvitegravir or Dolutegravir
  • Patient can be Hepatitis C positive as long as they are not being treated or plan to be treated during the study.

GS-0117

You may qualify for this study if the following applies to you:

  • HIV positive
  • VL > 500 copies/mL, but < 100,000 copies/mL
  • Estimated glomerular filtration rate ≥ 50 mL/min
  • Currently taking a failing ARV regimen

GS-1089

You may qualify for this study if the following applies to you:

  • HIV positive
  • VL < 50 copies/mL
  • Estimated glomerular filtration rate ≥ 50 mL/min
  • Currently receiving antiretroviral regimen containing Truvada in combination with one third agent

ING177172

You may qualify for this study if the following applies to you:

  • HIV positive
  • Female
  • VL > 200 copies/mL
  • CD4 > 200
  • HLA-B5701 negative
  • No previous use of HIV medications

EMR-500

You may qualify for this study if the following applies to you:

  • HIV positive
  • Stable ART for at least 8 weeks
  • Type 2 diabetes mellitus
  • Physical evidence of abdominal lipohypertrophy
  • Using lipid lowering drugs for at least 2 months